Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Issues spotlight: Medical cannabis

Issues spotlight: Medical cannabis 779904 CPHXXX10.1177/1715163518779904C P J / R P CC P J / R P C research-article2018 CPhACONNECTION CPhA ConneCtion of cannabis, including participating in the Task CPhA’s position Force on Cannabis Legalization and Regulations As medication experts, pharmacists are best and appearing before the House of Commons equipped to provide clinical advice to patients Standing Committee on Health. Throughout and appropriate oversight in the safe manage- each consultation, we emphasized how pro- ment and dispensing of medical cannabis. Phar- posed legislation could ae ff ct patients relying on macists have the necessary expertise to help medical cannabis as part of their drug therapy manage potential risks associated with medi- regimen. CPhA also oer ff ed statements and com- cal cannabis, including adverse effects, harmful mentary throughout 2016 and 2017 as the federal drug interactions, contraindications and poten- government debated the proposed regulations. tial addictive behaviour. Pharmacists also have Education and practice tools: CPhA has the existing infrastructure in place to handle developed a number of resources to help phar- controlled substances, as well as a secure sup- macists provide effective medication manage- ply chain to limit diversion. CPhA believes that ment for their patients using medical cannabis, pharmacist management and dispensing of including the following: medical cannabis is the best option to strengthen any future framework, improve access and pro- • Online CE programs: “An Introduction to tect patient and public safety. With governments Medical Cannabis and Cannabinoids” and moving to pass regulations and prepare for legal- “Medical Cannabis: Applying the Evidence ization in 2018, CPhA has consistently stressed to Practice” are oer ff ed free of charge to the need to maintain a robust medical canna- members of provincial pharmacy associa- bis stream and improve patient care and safety tions and Association of Faculties of Phar- through pharmacist dispensing. macy of Canada (AFPC) • Medical Cannabis FAQ Overview of CPhA activities • Cannabis for Medical Purposes Evidence Independent research: In February 2016, CPhA Guide commissioned Abacus Data to survey Canadi- CPhA continues to work on this file and is ans on their perceptions and attitudes towards committed to working with governments to marijuana. In March 2016, CPhA commissioned mitigate risk and enhance safety for Canadians. KPMG research into the key benefits that could Additional education and practice tools will be be expected from pharmacist management and released throughout 2018 to support pharma- dispensing of medical cannabis. cists across Canada. For more information on Government submissions: Over the past 2 CPhA’s efforts on medical cannabis, please visit years, CPhA has been actively involved in the www.pharmacists.ca/cannabis. ■ government’s consultations on the legalization © The Author(s) 2018 DOI: 10.1177/1715163518779904 274  CPJ/RPC• July / August2018•VOL151,NO4 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Canadian Pharmacists Journal / Revue des Pharmaciens du Canada SAGE

Issues spotlight: Medical cannabis

Download PDF
1 page

Loading next page...
 
/lp/sage/issues-spotlight-medical-cannabis-wVO00LAdJW

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
SAGE
Copyright
© The Author(s) 2018
ISSN
1715-1635
eISSN
1913-701X
DOI
10.1177/1715163518779904
Publisher site
See Article on Publisher Site

Abstract

779904 CPHXXX10.1177/1715163518779904C P J / R P CC P J / R P C research-article2018 CPhACONNECTION CPhA ConneCtion of cannabis, including participating in the Task CPhA’s position Force on Cannabis Legalization and Regulations As medication experts, pharmacists are best and appearing before the House of Commons equipped to provide clinical advice to patients Standing Committee on Health. Throughout and appropriate oversight in the safe manage- each consultation, we emphasized how pro- ment and dispensing of medical cannabis. Phar- posed legislation could ae ff ct patients relying on macists have the necessary expertise to help medical cannabis as part of their drug therapy manage potential risks associated with medi- regimen. CPhA also oer ff ed statements and com- cal cannabis, including adverse effects, harmful mentary throughout 2016 and 2017 as the federal drug interactions, contraindications and poten- government debated the proposed regulations. tial addictive behaviour. Pharmacists also have Education and practice tools: CPhA has the existing infrastructure in place to handle developed a number of resources to help phar- controlled substances, as well as a secure sup- macists provide effective medication manage- ply chain to limit diversion. CPhA believes that ment for their patients using medical cannabis, pharmacist management and dispensing of including the following: medical cannabis is the best option to strengthen any future framework, improve access and pro- • Online CE programs: “An Introduction to tect patient and public safety. With governments Medical Cannabis and Cannabinoids” and moving to pass regulations and prepare for legal- “Medical Cannabis: Applying the Evidence ization in 2018, CPhA has consistently stressed to Practice” are oer ff ed free of charge to the need to maintain a robust medical canna- members of provincial pharmacy associa- bis stream and improve patient care and safety tions and Association of Faculties of Phar- through pharmacist dispensing. macy of Canada (AFPC) • Medical Cannabis FAQ Overview of CPhA activities • Cannabis for Medical Purposes Evidence Independent research: In February 2016, CPhA Guide commissioned Abacus Data to survey Canadi- CPhA continues to work on this file and is ans on their perceptions and attitudes towards committed to working with governments to marijuana. In March 2016, CPhA commissioned mitigate risk and enhance safety for Canadians. KPMG research into the key benefits that could Additional education and practice tools will be be expected from pharmacist management and released throughout 2018 to support pharma- dispensing of medical cannabis. cists across Canada. For more information on Government submissions: Over the past 2 CPhA’s efforts on medical cannabis, please visit years, CPhA has been actively involved in the www.pharmacists.ca/cannabis. ■ government’s consultations on the legalization © The Author(s) 2018 DOI: 10.1177/1715163518779904 274  CPJ/RPC• July / August2018•VOL151,NO4

Journal

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada – SAGE

Published: Jul 1, 2018

There are no references for this article.